Kennedy Capital Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-20,408
| Closed | -$3.51M | – | 665 |
|
|
2021
Q3 | $3.51M | Sell |
20,408
-5,325
| -21% | -$697K | 0.08% | 409 |
|
|
2021
Q2 | $3.23M | Buy |
25,733
+241
| +0.9% | +$30.4K | 0.07% | 434 |
|
|
2021
Q1 | $3.46M | Sell |
25,492
-18,245
| -42% | -$2.36M | 0.07% | 443 |
|
|
2020
Q4 | $5.6M | Buy |
43,737
+1,356
| +3% | +$159K | 0.13% | 312 |
|
|
2020
Q3 | $4.77M | Sell |
42,381
-224
| -0.5% | -$22.3K | 0.14% | 286 |
|
|
2020
Q2 | $4.06M | Sell |
42,605
-2,020
| -5% | -$195K | 0.12% | 333 |
|
|
2020
Q1 | $4.01M | Sell |
44,625
-1,972
| -4% | -$153K | 0.15% | 258 |
|
|
2019
Q4 | $2.47M | Sell |
46,597
-50,757
| -52% | -$2.31M | 0.06% | 508 |
|
|
2019
Q3 | $3.85M | Sell |
97,354
-18,411
| -16% | -$799K | 0.1% | 401 |
|
|
2019
Q2 | $4.76M | Sell |
115,765
-905
| -0.8% | -$37.5K | 0.11% | 343 |
|
|
2019
Q1 | $5.43M | Buy |
+116,670
| New | +$5.12M | 0.13% | 303 |
|
|
2015
Q2 | – | Sell |
-23,762
| Closed | -$904K | – | 764 |
|
|
2015
Q1 | $904K | Buy |
23,762
+3,594
| +18% | +$143K | 0.02% | 661 |
|
|
2014
Q4 | $786K | Buy |
+20,168
| New | +$703K | 0.01% | 684 |
|
Kennedy Capital Management's XLRN Position: Q4 2021 in Review
Kennedy Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 20,408 shares — an estimated $3.51M sold.
Kennedy Capital Management first reported a position in XLRN in Q4 2014 and held it in 13 quarters. The position peaked at $5.6M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Kennedy Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Kennedy Capital Management sold 20,408 Acceleron Pharma shares in Q4 2021, an estimated $3.51M.
- Kennedy Capital Management first reported a position in Acceleron Pharma in Q4 2014 and held it in 13 quarters.
- Kennedy Capital Management's Acceleron Pharma position peaked at $5.6M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Kennedy Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.